# Avelumab in First-line NSCLC (JAVELIN Lung 100)

> **NCT02576574** · PHASE3 · COMPLETED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 1214 (actual)

## Conditions studied

- First Line Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Pemetrexed
- **DRUG:** Paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Avelumab Weekly

## Key facts

- **NCT ID:** NCT02576574
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-29
- **Primary completion:** 2021-12-06
- **Final completion:** 2024-01-29
- **Target enrollment:** 1214 (ACTUAL)
- **Last updated:** 2025-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02576574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02576574, "Avelumab in First-line NSCLC (JAVELIN Lung 100)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT02576574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*